The Role of Epidermal Growth Factor Receptor (EGFR) in the Efficacy of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients

Bulletin of Siberian Medicine - Russian Federation
doi 10.20538/1682-0363-2020-1-13-20
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Siberian State Medical University

Related search

Role of Epidermal Growth Factor Receptor in Breast Cancer

Breast Cancer Research and Treatment
Cancer ResearchOncology
2012English

Impact of Clinicopathological Characteristics on the Efficacy of Neoadjuvant Therapy in Patients With Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer

International Journal of Cancer
Cancer ResearchOncology
2017English

Delaying Chemotherapy in the Treatment of Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Clinical Medicine Insights: Oncology
Oncology
2015English

CD44v9 as a Poor Prognostic Factor of Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy

Breast Cancer
Nuclear MedicineRadiologyPharmacologyOncologyImagingMedicine
2018English

Epidermal Growth Factor Receptor (EGFR) in Biliary Tract Cancer

HPB
HepatologyGastroenterology
2016English

AXL/epidermal Growth Factor Receptor (EGFR) Complexes in Breast Cancer - Culprits for Resistance to EGFR Inhibitors?

Breast Cancer Research
Cancer ResearchOncology
2013English

Comparative Analysis of Different Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer

Tumors of female reproductive system
2017English

Neoadjuvant Chemotherapy: Role in Breast Cancer

2013English

The Prognostic Significance of Tumor Epidermal Growth Factor Receptor (EGFR) Expression Change After Neoadjuvant Chemoradiation in Patients With Rectal Adenocarcinoma

Wspolczesna Onkologia
OncologyRadiologyNuclear MedicineImaging
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy